vs
Huron Consulting Group Inc.（HURN）とRevvity（RVTY）の財務データ比較。上の社名をクリックして会社を切り替えられます
Revvityの直近四半期売上が大きい（$772.1M vs $442.0M、Huron Consulting Group Inc.の約1.7倍）。Revvityの純利益率が高く（12.7% vs 6.9%、差は5.8%）。Huron Consulting Group Inc.の前年同期比売上増加率が高い（10.7% vs 5.9%）。Revvityの直近四半期フリーキャッシュフローが多い（$161.8M vs $123.8M）。過去8四半期でHuron Consulting Group Inc.の売上複合成長率が高い（10.3% vs 9.0%）
ヒューロン・コンサルティング・グループは、ヘルスケア、ライフサイエンス、商業、高等教育の4分野を中心に経営コンサルティングサービスを提供する専門企業で、顧客の課題解決と持続的な成長を支援しています。
レブィティ（Revvity, Inc.）は米国のライフサイエンス・診断事業を手がける企業で、製薬およびバイオテクノロジー業界を主な顧客とし、特に新たな細胞治療や遺伝子治療の開発に関連するサービス・製品を提供している。前身は多岐にわたる事業を展開してきた老舗企業パーキンエルマーである。
HURN vs RVTY — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $442.0M | $772.1M |
| 純利益 | $30.7M | $98.4M |
| 粗利率 | — | — |
| 営業利益率 | 11.4% | 14.5% |
| 純利益率 | 6.9% | 12.7% |
| 売上前年比 | 10.7% | 5.9% |
| 純利益前年比 | -9.8% | 3.9% |
| EPS（希薄化後） | $1.71 | $0.86 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $442.0M | $772.1M | ||
| Q3 25 | $441.3M | $698.9M | ||
| Q2 25 | $411.8M | $720.3M | ||
| Q1 25 | $404.1M | $664.8M | ||
| Q4 24 | $399.3M | $729.4M | ||
| Q3 24 | $378.1M | $684.0M | ||
| Q2 24 | $381.0M | $691.7M | ||
| Q1 24 | $363.4M | $649.9M |
| Q4 25 | $30.7M | $98.4M | ||
| Q3 25 | $30.4M | $46.7M | ||
| Q2 25 | $19.4M | $53.9M | ||
| Q1 25 | $24.5M | $42.2M | ||
| Q4 24 | $34.0M | $94.6M | ||
| Q3 24 | $27.1M | $94.4M | ||
| Q2 24 | $37.5M | $55.4M | ||
| Q1 24 | $18.0M | $26.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
| Q4 25 | 11.4% | 14.5% | ||
| Q3 25 | 11.3% | 11.7% | ||
| Q2 25 | 11.1% | 12.6% | ||
| Q1 25 | 8.1% | 10.9% | ||
| Q4 24 | 11.8% | 16.3% | ||
| Q3 24 | 11.2% | 14.3% | ||
| Q2 24 | 15.6% | 12.4% | ||
| Q1 24 | 5.5% | 6.8% |
| Q4 25 | 6.9% | 12.7% | ||
| Q3 25 | 6.9% | 6.7% | ||
| Q2 25 | 4.7% | 7.5% | ||
| Q1 25 | 6.1% | 6.4% | ||
| Q4 24 | 8.5% | 13.0% | ||
| Q3 24 | 7.2% | 13.8% | ||
| Q2 24 | 9.8% | 8.0% | ||
| Q1 24 | 5.0% | 4.0% |
| Q4 25 | $1.71 | $0.86 | ||
| Q3 25 | $1.71 | $0.40 | ||
| Q2 25 | $1.09 | $0.46 | ||
| Q1 25 | $1.33 | $0.35 | ||
| Q4 24 | $1.82 | $0.77 | ||
| Q3 24 | $1.47 | $0.77 | ||
| Q2 24 | $2.03 | $0.45 | ||
| Q1 24 | $0.95 | $0.21 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $24.5M | $919.9M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $528.6M | $7.3B |
| 総資産 | $1.5B | $12.2B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $24.5M | $919.9M | ||
| Q3 25 | $23.9M | $931.4M | ||
| Q2 25 | $61.0M | $991.8M | ||
| Q1 25 | $23.4M | $1.1B | ||
| Q4 24 | $21.9M | $1.2B | ||
| Q3 24 | $18.5M | $1.2B | ||
| Q2 24 | $17.6M | $2.0B | ||
| Q1 24 | $18.6M | $1.7B |
| Q4 25 | $528.6M | $7.3B | ||
| Q3 25 | $499.8M | $7.4B | ||
| Q2 25 | $475.0M | $7.6B | ||
| Q1 25 | $494.3M | $7.6B | ||
| Q4 24 | $561.3M | $7.7B | ||
| Q3 24 | $522.8M | $7.9B | ||
| Q2 24 | $500.6M | $7.9B | ||
| Q1 24 | $495.6M | $7.8B |
| Q4 25 | $1.5B | $12.2B | ||
| Q3 25 | $1.5B | $12.1B | ||
| Q2 25 | $1.5B | $12.4B | ||
| Q1 25 | $1.4B | $12.4B | ||
| Q4 24 | $1.3B | $12.4B | ||
| Q3 24 | $1.3B | $12.8B | ||
| Q2 24 | $1.3B | $13.4B | ||
| Q1 24 | $1.3B | $13.4B |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $126.4M | $182.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $123.8M | $161.8M |
| FCFマージンFCF / 売上 | 28.0% | 21.0% |
| 設備投資強度設備投資 / 売上 | 0.6% | 2.6% |
| キャッシュ転換率営業CF / 純利益 | 4.12× | 1.85× |
| 直近12ヶ月FCF直近4四半期 | $183.0M | $509.4M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $126.4M | $182.0M | ||
| Q3 25 | $93.8M | $138.5M | ||
| Q2 25 | $80.0M | $134.3M | ||
| Q1 25 | $-106.8M | $128.2M | ||
| Q4 24 | $139.6M | $174.2M | ||
| Q3 24 | $85.2M | $147.9M | ||
| Q2 24 | $107.2M | $158.6M | ||
| Q1 24 | $-130.7M | $147.6M |
| Q4 25 | $123.8M | $161.8M | ||
| Q3 25 | $89.8M | $120.0M | ||
| Q2 25 | $78.0M | $115.5M | ||
| Q1 25 | $-108.7M | $112.2M | ||
| Q4 24 | $137.0M | $149.8M | ||
| Q3 24 | $82.8M | $125.6M | ||
| Q2 24 | $104.7M | $136.6M | ||
| Q1 24 | $-131.9M | $129.7M |
| Q4 25 | 28.0% | 21.0% | ||
| Q3 25 | 20.3% | 17.2% | ||
| Q2 25 | 18.9% | 16.0% | ||
| Q1 25 | -26.9% | 16.9% | ||
| Q4 24 | 34.3% | 20.5% | ||
| Q3 24 | 21.9% | 18.4% | ||
| Q2 24 | 27.5% | 19.7% | ||
| Q1 24 | -36.3% | 20.0% |
| Q4 25 | 0.6% | 2.6% | ||
| Q3 25 | 0.9% | 2.6% | ||
| Q2 25 | 0.5% | 2.6% | ||
| Q1 25 | 0.5% | 2.4% | ||
| Q4 24 | 0.7% | 3.4% | ||
| Q3 24 | 0.6% | 3.3% | ||
| Q2 24 | 0.6% | 3.2% | ||
| Q1 24 | 0.3% | 2.7% |
| Q4 25 | 4.12× | 1.85× | ||
| Q3 25 | 3.08× | 2.97× | ||
| Q2 25 | 4.12× | 2.49× | ||
| Q1 25 | -4.35× | 3.03× | ||
| Q4 24 | 4.11× | 1.84× | ||
| Q3 24 | 3.14× | 1.57× | ||
| Q2 24 | 2.86× | 2.87× | ||
| Q1 24 | -7.26× | 5.67× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
HURN
| Consulting And Managed Services Capability | $172.9M | 39% |
| Education | $118.7M | 27% |
| Commercial | $91.9M | 21% |
| Digital Capability | $54.6M | 12% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
